Sanntidsoppdatering for HLB Life Science Co., [067630.KQ]

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.